Valuation: Adimmune Corporation

Market Cap 7.5B 236M 206M 194M 176M 330M 22.62B 332M 2.32B 897M 11.5B 886M 866M 37B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 7.5B 236M 206M 194M 176M 330M 22.62B 332M 2.32B 897M 11.5B 886M 866M 37B EV / Sales 2026 *
4.95x
EV / Sales 2027 * 4.47x
Free-Float
70.19%
Yield 2026 *
-
Yield 2027 * -
1 day+0.28%
1 week+3.49%
Current month+0.28%
1 month+3.19%
3 months+2.30%
6 months-1.39%
Current year-6.07%
1 week 17.05
Extreme 17.05
17.85
1 month 17.05
Extreme 17.05
18.55
Current year 16.4
Extreme 16.4
21.5
1 year 16.4
Extreme 16.4
22.5
3 years 15.9
Extreme 15.9
36.6
5 years 15.9
Extreme 15.9
52.9
10 years 15.9
Extreme 15.9
79.8
Manager TitleAgeSince
Chief Executive Officer - 2019-06-19
Director of Finance/CFO - 2020-12-31
Chief Tech/Sci/R&D Officer - 2022-01-25
Director TitleAgeSince
Director/Board Member - 2019-06-19
Director/Board Member - 2011-08-14
Director/Board Member - 2017-06-28
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%+3.49%-2.47%-47.18% 236M
-0.58%+0.43%+32.58%-6.20% 78.37B
-2.55%+6.99%+510.30%+44.31% 61.5B
-1.11%+5.08%-11.48%-33.39% 59.78B
+0.14%-1.20%-11.21%+24.73% 46.53B
-0.24%+1.22%+2.36%+154.40% 45.5B
-1.62%-0.76%+51.23%-16.04% 31.84B
-1.81%+3.16%+44.82%+106.78% 25.4B
+0.47%+3.26%+4.94%+144.25% 21.43B
+0.27%+1.96%+59.19%+106.18% 15.77B
Average -0.68%+2.33%+68.03%+47.78% 38.64B
Weighted average by Cap. -0.92%+2.35%+94.84%+39.80%

Financials

2026 *2027 *
Net sales 1.52B 47.6M 41.51M 39.19M 35.59M 66.68M 4.57B 66.96M 469M 181M 2.32B 179M 175M 7.47B 1.68B 52.69M 45.95M 43.38M 39.39M 73.81M 5.06B 74.12M 520M 201M 2.57B 198M 194M 8.27B
Net income - -
Net Debt - -
Logo Adimmune Corporation
Adimmune Corp is a Taiwan-based company mainly engaged in the research, development, processing, manufacturing, and sales of serums, vaccines, diagnostic reagents, biological agents, bacterial cultures, and raw materials. The Company's main products are influenza vaccines and non-influenza vaccines. Tetanus vaccines are used to prevent tetanus. Influenza vaccines are used to prevent seasonal influenza viruses. Tuberculin skin tests are used to determine whether a patient is infected with Mycobacterium tuberculosis. The Company primarily sells its products domestically and internationally.
Employees
564
Date Price Change Volume
26-09-18 NT$17.80 +0.28% 805,993
26-09-17 NT$17.75 +2.90% 1,081,549
26-09-16 NT$17.25 +0.29% 314,081
26-09-15 NT$17.20 0.00% 668,255
26-09-14 NT$17.20 0.00% 498,289
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
17.80TWD
Average target price
21.00TWD
Spread / Average Target
+17.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4142 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!